Related Experiment Video
Updated: Jun 17, 2026
07:21
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Gastrointestinal stromal tumor: a bridge between bench and bedside
Toshirou Nishida1, Tsuyoshi Takahashi, Yasuaki Miyazaki
1Department of Surgery, Osaka Police Hospital, 10-31 Kitayama-cho, Tennouji-ku, Osaka 543-0035, Japan.
Summary
Gastrointestinal stromal tumors (GIST) treatment with imatinib and sunitinib is genotype-dependent. Resistance to these drugs can occur, necessitating further research into novel therapies for advanced GIST.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gastrointestinal stromal tumor (GIST) is driven by KIT or PDGFRA gene mutations.
- Complete surgical removal is curative, but targeted therapies are used for advanced GIST.
Purpose of the Study:
- To review the efficacy and resistance mechanisms of imatinib and sunitinib in GIST treatment.
- To highlight the genotype-dependent nature of drug response and resistance.
Main Methods:
- Literature review of GIST treatment, focusing on imatinib and sunitinib.
- Analysis of molecular mechanisms underlying drug resistance in GIST.
Main Results:
- Imatinib shows efficacy in advanced GIST but is subject to primary and acquired resistance.
- Sunitinib is effective against imatinib-resistant GIST but also faces resistance.
- Drug resistance mechanisms are often genotype-dependent.
Conclusions:
- Advanced GIST management may require multidisciplinary approaches.
- Understanding resistance patterns is crucial for developing new, more durable therapies.
